Yafu Yin1,2, Scott P Campbell3, Mark C Markowski4, Philip M Pierorazio3,4, Martin G Pomper1,3,4, Mohamad E Allaf3,4, Steven P Rowe1,3, Michael A Gorin5,6,7. 1. The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, China. 3. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 213, Baltimore, MD, 21287, USA. 4. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. mgorin1@jhmi.edu. 6. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 213, Baltimore, MD, 21287, USA. mgorin1@jhmi.edu. 7. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. mgorin1@jhmi.edu.
Abstract
PURPOSE: To investigate the utility of prostate-specific membrane antigen (PSMA)-targeted [18F]DCFPyL positron emission tomography (PET)/X-ray computed tomography (CT) imaging for the detection of sites of disease in patients with metastatic non-clear cell renal cell carcinoma (RCC). PROCEDURES: Eight patients with metastatic non-clear cell RCC underwent imaging with PSMA-targeted [18F]DCFPyL PET/CT. Imaged RCC histologic subtypes included papillary RCC (n = 3), chromophobe RCC (n = 2), unclassified RCC (n = 2), and Xp11 translocation RCC (n = 1). Using comparison to conventional CT and/or magnetic resonance imaging as reference, two radiologists with expertise in nuclear medicine identified putative sites of disease on [18F]DCFPyL PET/CT and classified each lesion as having no radiotracer uptake, equivocal uptake, or definitive uptake. RESUTS: In total, 73 metastatic sites and 3 primary tumors compatible with sites of non-clear cell RCC were identified on conventional imaging. Metastatic sites of disease included lymph nodes (n = 40), venous thrombi (n = 3), pulmonary nodules (n = 10), bone lesions (n = 15), brain lesions (n = 3), and retroperitoneal masses (n = 2). Only 10 of the 73 lesions (13.7 %) were classified as having definitive radiotracer uptake (median SUVmax = 3.25, range = 1.2-9.5), 14 lesions (19.2 %) had equivocal uptake (median SUVmax = 2.85, range = 0.5-6.5), and 49 lesions (67.1 %) had no definitive uptake above background (median SUVmax = 1.7, range = 0.2-3.0). The three primary renal tumors demonstrated lower radiotracer avidity relative to surrounding normal renal parenchyma. CONCLUSIONS: A small proportion of sites of non-clear cell RCC showed uptake of the PSMA-targeted radiotracer [18F]DCFPyL. Unlike for clear cell RCC, the results of this study indicate that PSMA-based PET is not appropriate for imaging other RCC subtypes.
PURPOSE: To investigate the utility of prostate-specific membrane antigen (PSMA)-targeted [18F]DCFPyL positron emission tomography (PET)/X-ray computed tomography (CT) imaging for the detection of sites of disease in patients with metastatic non-clear cell renal cell carcinoma (RCC). PROCEDURES: Eight patients with metastatic non-clear cell RCC underwent imaging with PSMA-targeted [18F]DCFPyL PET/CT. Imaged RCC histologic subtypes included papillary RCC (n = 3), chromophobe RCC (n = 2), unclassified RCC (n = 2), and Xp11 translocation RCC (n = 1). Using comparison to conventional CT and/or magnetic resonance imaging as reference, two radiologists with expertise in nuclear medicine identified putative sites of disease on [18F]DCFPyL PET/CT and classified each lesion as having no radiotracer uptake, equivocal uptake, or definitive uptake. RESUTS: In total, 73 metastatic sites and 3 primary tumors compatible with sites of non-clear cell RCC were identified on conventional imaging. Metastatic sites of disease included lymph nodes (n = 40), venous thrombi (n = 3), pulmonary nodules (n = 10), bone lesions (n = 15), brain lesions (n = 3), and retroperitoneal masses (n = 2). Only 10 of the 73 lesions (13.7 %) were classified as having definitive radiotracer uptake (median SUVmax = 3.25, range = 1.2-9.5), 14 lesions (19.2 %) had equivocal uptake (median SUVmax = 2.85, range = 0.5-6.5), and 49 lesions (67.1 %) had no definitive uptake above background (median SUVmax = 1.7, range = 0.2-3.0). The three primary renal tumors demonstrated lower radiotracer avidity relative to surrounding normal renal parenchyma. CONCLUSIONS: A small proportion of sites of non-clear cell RCC showed uptake of the PSMA-targeted radiotracer [18F]DCFPyL. Unlike for clear cell RCC, the results of this study indicate that PSMA-based PET is not appropriate for imaging other RCC subtypes.
Authors: Frederik A Verburg; Thomas Krohn; Alexander Heinzel; Felix M Mottaghy; Florian F Behrendt Journal: Eur J Nucl Med Mol Imaging Date: 2015-04-28 Impact factor: 9.236
Authors: Arun Sasikumar; Ajith Joy; M R A Pillai; Raviteja Nanabala; Muhammed Anees K; P G Jayaprakash; Jayaprakash Madhavan; Suresh Nair Journal: Clin Nucl Med Date: 2017-01 Impact factor: 7.794
Authors: Steven Campbell; Robert G Uzzo; Mohamad E Allaf; Eric B Bass; Jeffrey A Cadeddu; Anthony Chang; Peter E Clark; Brian J Davis; Ithaar H Derweesh; Leo Giambarresi; Debra A Gervais; Susie L Hu; Brian R Lane; Bradley C Leibovich; Philip M Pierorazio Journal: J Urol Date: 2017-05-04 Impact factor: 7.450
Authors: Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex Journal: Eur Urol Date: 2015-01-21 Impact factor: 20.096
Authors: Steven P Rowe; Michael A Gorin; Hans J Hammers; M Som Javadi; Hazem Hawasli; Zsolt Szabo; Steve Y Cho; Martin G Pomper; Mohamad E Allaf Journal: Ann Nucl Med Date: 2015-08-19 Impact factor: 2.668
Authors: Mike Sathekge; Thabo Lengana; Moshe Modiselle; Mariza Vorster; JanRijn Zeevaart; Alex Maes; Thomas Ebenhan; Christophe Van de Wiele Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-08 Impact factor: 9.236
Authors: Chiara Pozzessere; Maria Bassanelli; Anna Ceribelli; Sazan Rasul; Shuren Li; John O Prior; Francesco Cicone Journal: Curr Urol Rep Date: 2019-10-11 Impact factor: 3.092
Authors: Falk Gühne; Philipp Seifert; Bernhard Theis; Matthias Steinert; Martin Freesmeyer; Robert Drescher Journal: Diagnostics (Basel) Date: 2021-06-23
Authors: Christophe Van de Wiele; Mike Sathekge; Bart de Spiegeleer; Pieter Jan de Jonghe; Laurence Beels; Alex Maes Journal: Int J Mol Sci Date: 2019-10-02 Impact factor: 5.923
Authors: Rudolf A Werner; Thorsten Derlin; Constantin Lapa; Sara Sheikbahaei; Takahiro Higuchi; Frederik L Giesel; Spencer Behr; Alexander Drzezga; Hiroyuki Kimura; Andreas K Buck; Frank M Bengel; Martin G Pomper; Michael A Gorin; Steven P Rowe Journal: Theranostics Date: 2020-01-01 Impact factor: 11.556
Authors: M J M Uijen; Y H W Derks; W A M van Gemert; J Nagarajah; R I J Merkx; M G M Schilham; J Roosen; B M Privé; S A M van Lith; C M L van Herpen; M Gotthardt; S Heskamp Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-12 Impact factor: 9.236